Kenneth C. Cundy, SVP, Preclinical Development at XENOPORT INC (XNPT), sold 2,600 shares at $26.87 ($70K) on 2009-02-02, disclosed to the SEC on 2009-02-03.
Scheduled sale ($70k) by SVP, Preclinical Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.26 | 100 | $3K | 3.8% |
| 2 | $26.28 | 100 | $3K | 3.8% |
| 3 | $26.49 | 100 | $3K | 3.8% |
| 4 | $26.56 | 100 | $3K | 3.8% |
| 5 | $26.62 | 100 | $3K | 3.8% |
| 6 | $26.63 | 71 |
| $2K |
| 2.7% |
| 7 | $26.64 | 100 | $3K | 3.8% |
| 8 | $26.67 | 29 | $773 | 1.1% |
| 9 | $26.72 | 100 | $3K | 3.8% |
| 10 | $26.75 | 100 | $3K | 3.8% |
| 11 | $26.79 | 200 | $5K | 7.7% |
| 12 | $26.80 | 100 | $3K | 3.8% |
| 13 | $26.81 | 100 | $3K | 3.8% |
| 14 | $26.83 | 100 | $3K | 3.9% |
| 15 | $26.85 | 100 | $3K | 3.9% |
| 16 | $26.87 | 100 | $3K | 3.9% |
| 17 | $26.89 | 99 | $3K | 3.8% |
| 18 | $26.91 | 1 | $27 | 0.0% |
| 19 | $26.92 | 100 | $3K | 3.9% |
| 20 | $26.93 | 100 | $3K | 3.9% |
| 21 | $26.94 | 200 | $5K | 7.7% |
| 22 | $26.95 | 100 | $3K | 3.9% |
| 23 | $26.96 | 100 | $3K | 3.9% |
| 24 | $26.97 | 100 | $3K | 3.9% |
| 25 | $27.10 | 100 | $3K | 3.9% |
| 26 | $27.12 | 100 | $3K | 3.9% |
| Total | $26.79 avg | 2,600 | $70K | 100% |
| Filing → |
| CWBR | SELL | 2020-08-10 | $19K | — | Filing → |
| CWBR | SELL | 2020-06-17 | $24K | — | Filing → |
| CWBR | SELL | 2020-05-18 | $26K | — | Filing → |